Friday, February 28, 2014
Press Release: Carnegie Mellon's James W. Schneider Named Fellow of American Institute for Medical and Biological Engineering
He Develops Synthetic DNA-like Materials for Bio-Analytical Devices, Pharmaceutical Processing and Drug Delivery
Contact: Chriss Swaney / 412-268-5776 / firstname.lastname@example.org
PITTSBURGH—Carnegie Mellon University's James W. Schneider has been elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE) for leading-edge research on the development of novel materials for biosensing. He will be honored March 24 by AIMBE at the National Academy of Sciences in Washington, D.C.
"It's very gratifying to have our group's work recognized this way," said Schneider, a professor of chemical engineering and biomedical engineering. "The high-speed, gel-free DNA analysis methods we have developed will provide faster, cheaper, and more reliable routes to medical diagnostics and forensic identification."
Schneider's work focuses on the development of synthetic DNA-like materials for bio-analytical devices, pharmaceutical processing and drug delivery.
Milan P. Yager, executive director of AIMBE, said Schneider's election to fellow was a direct result of his important contributions to biomedical engineering.
"This is wonderful recognition for an outstanding researcher and dynamic teacher whose energy and dedication are essential to the university's successful multidisciplinary research culture," said Lorenz Biegler, the Bayer Professor and head of Chemical Engineering at CMU. "He joins a select group of outstanding CMU researchers with AMBE fellow status."
Other CMU awardees in past years have included Phil LeDuc, Todd Przybycien, Bob Tilton, Mike Domach, Jim Antaki, Bob Murphy, Alan Russell and Alan Waggoner.
Founded in 1991, AIMBE is an advocate on issues impacting the medical and biological engineering community. AIMBE played a pivotal role in helping establish the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health and is now a founding member of the FDA's Network of Experts, a new program connecting FDA regulators with the AIMBE's College of Fellows. The College of Fellows includes 1,500 individuals from academia, government and industry.
James Schneider (pictured above), a professor of chemical engineering and biomedical engineering, is working on the development of synthetic DNA-like materials for bio-analytical devices, pharmaceutical processing and drug delivery.